TS

Neupulse Secures Funding to Advance World’s First Wearable Device to Tackle Tourettes Syndrome

Retrieved on: 
Monday, March 18, 2024
Wearables, Mobile Technology, Technology, Medical Devices, Neurology, Health Technology, Biotechnology, Hardware, Health, General Health, Tic, University, Education, TS, Eos, Tourette syndrome, Quality of life, Pain, Median nerve, Multimedia, Wrist, Work, Social integration, Pharmaceutical industry

Neupulse has secured funding to advance the world’s first wearable device aimed at tackling Tourettes Syndrome (TS) and other tic disorders towards commercialization.

Key Points: 
  • Neupulse has secured funding to advance the world’s first wearable device aimed at tackling Tourettes Syndrome (TS) and other tic disorders towards commercialization.
  • Clinical trials in 2023 showed the Neupulse device can reduce tics by over 25 percentile.
  • Tourettes Syndrome is a neurological condition characterized by involuntary, repetitive movements and vocalizations known as tics.
  • Our device is an alternative to the current provision of treatment for TS, which is centred around medication and cognitive behaviour therapy.

Rittal Announces Colocation Rack Initiative to Meet the Growing Demand for Colocation Market

Retrieved on: 
Friday, March 1, 2024
Marketing, Rittal, MDC, TS, Micro data center

SCHAUMBURG, Ill., March 1, 2024 /PRNewswire/ -- Rittal LLC, a leader in providing infrastructure solutions for IT applications, launches its new line of enclosures designed for the colocation market.

Key Points: 
  • SCHAUMBURG, Ill., March 1, 2024 /PRNewswire/ -- Rittal LLC, a leader in providing infrastructure solutions for IT applications, launches its new line of enclosures designed for the colocation market.
  • Developed based on key feedback, the new initiative will accelerate and grow the success of all parties involved in the colocation market with comprehensive education, sales support, and marketing resources.
  • Cassiano Fabris, Vice President of Global Key Accounts for Rittal, stated how the colocation market is evolving, saying, "The colocation market is continuously growing at impressive speeds.
  • The TS IT Colo ensures that data centers not only meet the requirements of colocation operators, but also cover the essential needs of the market and remain fit for the future.

ICE Bonds Broadens Its Fixed Income Liquidity Network with Connectivity to TS Imagine

Retrieved on: 
Monday, February 5, 2024
Technology, Finance, Fintech, Banking, Professional Services, Software, Data Analytics, Asset Management, Data Management, Intercontinental, Intercontinental Exchange, Municipal bond, TS, ICE, RFQ, Security (finance)

Intercontinental Exchange, Inc. (NYSE: ICE), a leading global provider of technology and data, today announced that TS Imagine has connected to ICE Bonds to offer clients seamless access to its fixed income execution protocols and liquidity.

Key Points: 
  • Intercontinental Exchange, Inc. (NYSE: ICE), a leading global provider of technology and data, today announced that TS Imagine has connected to ICE Bonds to offer clients seamless access to its fixed income execution protocols and liquidity.
  • TS Imagine customers using the TS One and TradeSmart OEMS can now access ICE Bonds’ trading protocols for Municipals and Corporates, across the ICE TMC and ICE BondPoint platforms.
  • “TS Imagine’s cross-asset platform has become a leading tool for investors around the world and we’re pleased to be delivering ICE Bonds’ streaming municipal and corporate bond data and liquidity to their customers,” said Peter Borstelmann, President of ICE Bonds.
  • By electing to use the ICE Bonds API for connectivity, TS Imagine’s customers will have access to diverse pools of fixed income liquidity via the ICE Bonds’ suite of trading protocols, including click-to-trade and request-for-quote (RFQ).

2seventy bio Announces New Strategic Path Forward

Retrieved on: 
Tuesday, January 30, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Partnership, ODAC, Multiple myeloma, Growth, Bristol Myers Squibb, CMO, Science, Research, Trial of the century, GV (company), Patient, AML, BMS, BCMA, LVV, Ovarian cancer, MUC16, Physician, Autoimmunity, APA, TS, PDUFA, Webcast, Workforce, Johnson & Johnson, Management

2seventy bio, in partnership with Bristol Myers Squibb (BMS), is taking actions to return Abecma to commercial growth in 2024.

Key Points: 
  • 2seventy bio, in partnership with Bristol Myers Squibb (BMS), is taking actions to return Abecma to commercial growth in 2024.
  • 2seventy bio and BMS are expanding its Abecma site footprint to enable more patients to access the treatment.
  • Upon closing of the transaction with Regeneron, Chip Baird, chief operating officer, will become chief executive officer of 2seventy bio.
  • After 13 years of service on the bluebird bio and 2seventy bio Board of Directors, Dan Lynch will step down from the Board in June and will continue in an advisory role for 2seventy bio.

David Werner Real Estate Investments Secures Long-term Lease Extension with Dow at Collegeville, Pennsylvania Life Sciences Campus

Retrieved on: 
Tuesday, January 16, 2024
TS, Research, Science, History, Medicine, Tenant, Personal care, Pleasure, Growth, Commercial property

NEW YORK and MORRISTOWN, N.J., Jan. 16, 2024 /PRNewswire/ -- David Werner Real Estate Investments (DWREI) today announced the signing of a long-term lease extension with Dow, a global materials science company, at its life sciences and office campus in Collegeville, Pa. Dow, whom Newmark Group represents, has agreed to an extension of its lease term for approximately 800,000 square feet that includes the company's Northeast Dow Center, a significant research and development center for the company. 

Key Points: 
  • NEW YORK and MORRISTOWN, N.J., Jan. 16, 2024 /PRNewswire/ -- David Werner Real Estate Investments (DWREI) today announced the signing of a long-term lease extension with Dow , a global materials science company, at its life sciences and office campus in Collegeville, Pa. Dow, whom Newmark Group represents, has agreed to an extension of its lease term for approximately 800,000 square feet that includes the company's Northeast Dow Center, a significant research and development center for the company.
  • DWREI and its partner GreenBarn Investment Group completed the purchase of the campus this past August from Pfizer Inc., who remains a tenant at the property.
  • Spanning approximately 1.9 million square feet and located just 22 miles northwest of Downtown Philadelphia, the campus includes 14 interconnected office, life science and mixed-use office buildings across 340 acres.
  • We look forward to continuing to serve Dow and Pfizer, a blue-chip organization with a 170-year history centered on innovation in science, medicine and healthcare."

Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

Retrieved on: 
Thursday, January 4, 2024
PIN, TS, EFS, Kite Pharma, Cancer, Conference, B-cell lymphoma, Disease, Steroid, CLL, Lymphocyte, First Line, CRS, Safety, News, Patient, Cyclophosphamide, MRD, AID, Cytokine release syndrome, Therapy, CF1, CD70, Biology, Westin St. Francis, Autoimmune disease, Renal cell carcinoma, SAN, Standard of care, Demand, Observation, RCC, CD19, Vaccine

“Until now, CAR T development has been defined by how autologous CAR Ts are made and used.

Key Points: 
  • “Until now, CAR T development has been defined by how autologous CAR Ts are made and used.
  • The standard of care after 1L treatment has been simply to “watch and wait” for the disease to relapse.
  • ALPHA3 builds on the growing understanding that administration of CAR T therapies to patients with low disease burden improves both safety and efficacy outcomes.
  • The 2024 Platform Vision Conference Call will be hosted on Thursday, January 4, 2024, at 2:00 p.m. PT/5:00 p.m.

Knightscope Authorized Partner TS&L Purchases First 13 K1 Blue E-Phones for Georgia State University

Retrieved on: 
Tuesday, January 2, 2024
Public Policy, Government, Telecommunications, Software, Robotics, Public Safety, Technology, Mobile, Wireless, Security, Safety, Security Division (Wehrmacht), Knightscope, Georgia State University, TS, Transport, Mobile phone

Knightscope, Inc. [Nasdaq: KSCP] (“Knightscope” or the “Company”), a leading developer of autonomous security robots and blue light emergency communication systems, today announces its first order of 13 K1 Blue Light E-Phones for Georgia State University (“GSU”) by Knightscope Authorized Partner (“KAP”) Transportation Solutions & Lighting, Inc., – Safety and Security Division – National Safety Systems (“NSS/TS&L”).

Key Points: 
  • Knightscope, Inc. [Nasdaq: KSCP] (“Knightscope” or the “Company”), a leading developer of autonomous security robots and blue light emergency communication systems, today announces its first order of 13 K1 Blue Light E-Phones for Georgia State University (“GSU”) by Knightscope Authorized Partner (“KAP”) Transportation Solutions & Lighting, Inc., – Safety and Security Division – National Safety Systems (“NSS/TS&L”).
  • As announced in July 2023 , this is the first of what is ultimately expected to be more than 50 emergency communication devices to be installed at the downtown Atlanta campus by TS&L.
  • View the full release here: https://www.businesswire.com/news/home/20240102788571/en/
    Knightscope Authorized Partner TS&L Purchases First 13 K1 Blue E-Phones for Georgia State University (Photo: Business Wire)
    The bright blue lights on Knightscope's K1 emergency phones lead those in need to fixed locations for accessing dependable communications away from buildings, when a cellphone battery dies, or there is simply no service available.
  • At the push of a button, a student, guest or teacher may call security for immediate assistance in the event of an emergency.

SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication

Retrieved on: 
Friday, November 10, 2023
Ministry, Safety, TS, Food, Yale University, Disorder, THC, Clinical trial, Medical device, Patient, IIA, FDA, Movement, Hannover Medical School, Cannabinoid, Tourette syndrome, Learning, Central nervous system, Tic, TEL, PEA, Pharmaceutical industry, Dronabinol, Health

TEL AVIV, Israel, Nov. 10, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced the initiation of its Phase IIb clinical trial treating patients suffering from Tourette Syndrome (TS) with its SCI-110, proprietary drug candidate.

Key Points: 
  • SciSparc initiated the trial at the Tel Aviv Sourasky Medical Center in Israel (Sourasky) and is expected to proceed with its U.S. and Germany-based medical sites.
  • TS is a movement and neurobehavioral disorder characterized by motor and vocal tics and is highly linked with co-morbidities.
  • The patients will be randomized at a 1:1 ratio to receive either SCI-110 or a SCI-110-matched placebo.
  • In addition, the medication was generally well-tolerated by subjects and 12 out of the 16 subjects elected to continue into a 24-week extension phase of the trial.

TS Conductor Wins Rising Star Company at S&P Global Commodity Insights' 25th Annual Platts Global Energy Awards

Retrieved on: 
Monday, December 18, 2023
Television, Tennessee Valley Authority, NextEra Energy, TS, S&P Global Commodity Insights, History, CNBC, Basin Electric Power Cooperative, Breakthrough Energy, MDU, Electricity, TVA, SRP, Electric power, Award

HUNTINGTON BEACH, Calif., Dec. 18, 2023 /PRNewswire-PRWeb/ -- TS Conductor, a pioneer in high-performance transmission and distribution conductors for electricity grids, received the Rising Star Company award at the 25th Annual Platts Global Energy Awards.

Key Points: 
  • HUNTINGTON BEACH, Calif., Dec. 18, 2023 /PRNewswire-PRWeb/ -- TS Conductor, a pioneer in high-performance transmission and distribution conductors for electricity grids, received the Rising Star Company award at the 25th Annual Platts Global Energy Awards.
  • An independent panel of judges chose the winners of the 2023 Platts Global Energy Awards from finalists selected from nominations that represented 33 different countries.
  • TS is backed by investors such as Breakthrough Energy Ventures, National Grid Partners, NextEra Energy, and others.
  • For details on all of the winners of this year's Platts Global Energy Awards, access the December issue of the S&P Global Commodity Insights Magazine or visit the Platts Global Energy Awards website .

SUBARU BRZ SECURES THIRD-CONSECUTIVE 'CAR AND DRIVER' 10BEST AWARD

Retrieved on: 
Tuesday, December 5, 2023
Sale, STI, DNA, TS, SUBARU, Subaru of America, Car, SUV, Manual, Brembo, Sport, Toyota 86, BRZ, Automotive industry, Subaru

Latest-generation Subaru BRZ nets high praise as affordable, fun sports car

Key Points: 
  • Latest-generation Subaru BRZ nets high praise as affordable, fun sports car
    CAMDEN, N.J., Dec. 5, 2023 /PRNewswire/ -- Subaru of America, Inc. announced today the Subaru BRZ was selected by editors at Car and Driver for its annual 10Best Cars honor in 2024.
  • "Manual, rear-drive, and engineered to delight, drivers looking for affordable performance need to look no further than the Subaru BRZ," said Car and Driver Editor-in-Chief Tony Quiroga.
  • The 10Best Cars of 2024 nominees consist of all-new vehicles, significantly updated vehicles and 10Best winners from 2023.
  • The Subaru BRZ tS adds an uprated Brembo braking system, STI-tuned front and rear Hitachi® dampers, and unique interior and exterior details.